Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
29 oct. 2019 19h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) has today announced that Telix and AusHealth have entered into a collaboration...
Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
22 oct. 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference
30 sept. 2019 14h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief...
Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
27 sept. 2019 10h15 HE
|
Aravive, Inc.
HOUSTON, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today presented positive data from the initial 12 patients of the ongoing Phase 1b portion of the company’s Phase 1b/2 study...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
28 août 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
05 août 2019 16h05 HE
|
Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerInitiated Phase 1/2a clinical trial for...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
31 juil. 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Cancer Treatment Centers of America Offers Heated Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for Ovarian Cancer Patients
20 juin 2019 16h49 HE
|
Cancer Treatment Centers of America, Chicago
Chicago, Ill., June 20, 2019 (GLOBE NEWSWIRE) -- In March, the National Comprehensive Cancer Network (NCCN) released updated guidelines stating that Heated Intraperitoneal Chemotherapy (HIPEC)...
Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 08h30 HE
|
Harpoon Therapeutics
Continued enrollment of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerNet proceeds of approximately $71 million from completion...
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
18 avr. 2019 07h30 HE
|
Harpoon Therapeutics
HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...